Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders. - Wikidata - awgldk - TriplyDB

Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.

Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.

http://www.wikidata.org/entity/Q37355856

about

Rituximab, Dexamethasone, Cytarabine, and Cisplatin as Effective Platinum-Based Salvage Chemotherapy for Periportal Posttransplant Lymphoproliferative Disorder After an Orthotopic Liver Transplant.

P2860

Q42193961-DB1E4E77-F8F9-4D1E-9FB2-0C1A8BD7CEE3

P2860

Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.

http://www.wikidata.org/entity/Q37355856

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@en

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@nl

type

label

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@en

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@nl

prefLabel

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@en

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@nl

P1433

Q37355856-5D5F99AE-1183-43B9-8320-0C8F1A84D73F

P1476

Q37355856-47FEDAA3-D93C-46C1-920C-9956EC716EC2

P2093

Q37355856-19C01018-4004-4921-A3F9-6D59C0B1AF07

Q37355856-4314380A-6A5C-4578-8EBE-5949BF4FCB49

Q37355856-504A1D72-57B3-45EB-9549-244ABFFD2B19

Q37355856-6FF561F3-A8A7-4C10-8D2F-E64B1D99D03F

Q37355856-C06491DA-C561-4BEA-8ED7-4481DDAEC004

Q37355856-DB6A46A2-B5C6-402E-82EB-36B3D4E6DCE5

P2860

Q37355856-0E066D46-EEDD-4B4F-B2C2-182380193B42

Q37355856-14C6B5CA-D0E4-48AF-9D6F-02E763036F7A

Q37355856-200EBAE7-7CF1-4989-B559-4768F8EF4112

Q37355856-31A59F16-DDCA-4D9A-A764-34A7D54CBECB

Q37355856-3B1B6CCC-C771-488A-996F-131FAE1090D0

Q37355856-3ED4754F-2982-4B14-9FBF-062519B53252

Q37355856-45C2686C-60C3-4419-BD94-E997989BE59D

Q37355856-4797F956-7AC1-4659-B0A5-853E5DAB4345

Q37355856-4F64F4DC-6731-4DA2-AD59-2FF56132B6A9

Q37355856-54E59FCB-8FD7-4097-8C6B-C7E46E31D914

P304

Q37355856-E391B775-8292-4361-9F8C-E0999719FF62

P31

Q37355856-32A5CE0F-6A83-499F-82B2-C5F6F432786A

P356

Q37355856-455F1009-2CFA-4C3F-877A-D07A55CF7A00

P407

Q37355856-E250E7C5-39DF-4074-9D3D-BB2356E5CEE7

P433

Q37355856-8B99BC70-2CF3-47F2-8486-E8A92ED36312

P478

Q37355856-45F0ED79-2AB4-4E14-B4F8-A8CB56A06397

P577

Q37355856-49822602-B193-417A-991C-B830C627EC76

P698

Q37355856-66EA1E09-B6AB-4FDA-81F4-F22DB74AF456

P921

Q37355856-483234B2-025E-4714-A05A-275791920628

P932

Q37355856-0B664D42-75EA-4524-8BD1-776FA3A69CDC

P356

J.CLML.2013.07.006

P1433

Clinical Lymphoma, Myeloma & Leukemia

P1476

Chemoimmunotherapy and withdra ...... lymphoproliferative disorders.

@en

P2093

Bingnan Zhang

http://www.w3.org/2001/XMLSchema#string

Dennis L Cooper

http://www.w3.org/2001/XMLSchema#string

Ivan Bustillo

http://www.w3.org/2001/XMLSchema#string

Nikolai Podoltsev

http://www.w3.org/2001/XMLSchema#string

Xiaopan Yao

http://www.w3.org/2001/XMLSchema#string

Yanhong Deng

http://www.w3.org/2001/XMLSchema#string

P2860

The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders.

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder.

Epstein-Barr virus infection.

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★).

Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.

Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.

EBV-associated lymphoproliferative disorders: classification and treatment.

P304

716-720

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLML.2013.07.006

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24035715

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

3846604

http://www.w3.org/2001/XMLSchema#string